Sign in
TerminatedPhase 2

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

Key facts

Who runs it
Intercept Pharmaceuticals
Where
Baltimore, Boston, Charleston, Chicago, Dallas, Detroit, Fresno, Houston, Manhasset, Miami, Nashville, New York, Palo Alto, Philadelphia, Richmond, Rochester, Sacramento, Salt Lake City, Tampa, and Worcester, United StatesSee the 20 sitesAlso in 2 other countries, 9 sites
Status
Terminated
Phase
Phase 2
People taking part
67 people enrolled
Started
15 Dec 2022
Ended
10 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • INT-787
  • Placebo
Record updated
5 May 2026
Why it stopped
Intercept made the business decision to terminate the study on 31 Mar 2026 as there was no clear evidence of potential benefit of INT-787 in sAH. This decision was not based on a safety concern.

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Males or females aged 18 to 65 years (inclusive)
  • Clinical diagnosis of sAH based on all the following:; History of ongoing excess alcohol (>60 g/day [male] or >40 g/day [female]) use for ≥6 months, with <60 days of abstinence prior to the onset of jaundice; Serum total bilirubin >3.0 mg/dL; Aspartate aminotransferase (AST) ≥50 U/L; AST/Aspartate aminotransferase (ALT) ratio ≥1.5; Onset of jaundice within prior 8 weeks; Cohort 1 through Cohort 4: Maddrey's Discriminant Factor (mDF) ≥32 and ≤70; Cohort 5 and Cohort 6: mDF ≥32
  • Cohort 1 through Cohort 4: MELD score ≥18 to ≤25 (inclusive) and Cohort 5 and Cohort 6: MELD score ≥21 to ≤30
  • Female participants must be postmenopausal, surgically sterile, or, if premenopausal (and not surgically sterile), be prepared to use ≥1 highly effective method of contraception from the initiation of Screening and for 90 days after the last dose of investigational product as follows:; Surgical sterilization (bilateral tubal occlusion, etc.); Placement of an intrauterine device (IUD) or intrauterine system (e.g., intrauterine hormone-releasing system [IUS]); Combined (estrogen and progesterone containing) hormonal contraceptive associated with inhibition of ovulation:; Oral; Intravaginal; Transdermal; Progesterone-only hormonal contraception associated with inhibition of ovulation:; Oral; Injectable; Implantable; Sexual abstinence: When in line with the preferred and usual lifestyle of the participant, is defined as avoiding all types of activity that could result in conception (pregnancy) from the initiation of Screening and until at least 90 days after the last dose of investigational product

Who cannot take part

  • Participants taking products containing obeticholic acid in the 30 days prior to randomization
  • Participants taking >2 doses of systemic corticosteroids within 30 days prior to randomization
  • Participants who have been inpatient at a referral hospital for >7 days prior to transfer
  • Abstinence from alcohol consumption for >2 months before Day 1
  • Current or previous history of hepatocellular carcinoma (HCC)
  • Other causes of liver disease including chronic hepatitis B (hepatitis B surface antigen [HBsAg] positive), chronic hepatitis C virus (HCV) RNA positive, drug-induced liver injury (DILI), biliary obstruction, and autoimmune liver disease
  • History of liver transplantation or currently listed for liver transplant; Note: Additional protocol defined Inclusion/Exclusion criteria apply
  • AST or ALT >400 U/L
  • Pregnancy, planned pregnancy, potential for pregnancy (e.g., unwillingness to use effective birth control during the study), or current or planned breast feeding
  • Cohort 1 through Cohort 4: mDF <32 or >70
  • Cohort 5 and Cohort 6: mDF <32
  • Cohort 1 through Cohort 4: MELD score <18 or >25
  • Cohort 5 and Cohort 6: MELD <21 or >30

Where in United States

Also in 2 other countries, 9 sites

  • Mercy Medical CenterBaltimore, United States
  • Beth Israel Deaconess Medical CenterBoston, United States
  • Medical University of South CarolinaCharleston, United States
  • Rush University Medical CenterChicago, United States
  • The Liver Institute at Methodist Dallas Medical CenterDallas, United States
  • Henry Ford Health SystemDetroit, United States
  • University of California San Francisco-FresnoFresno, United States
  • Baylor College of MedicineHouston, United States
  • Northwell Health Center for Liver Disease and TransplantationManhasset, United States
  • Miami, FloridaHospital not named in the registry
  • Vanderbilt Digestive Disease CenterNashville, United States
  • Columbia University Medical Center/New York-Presbyterian HospitalNew York, United States
  • Stanford HealthcarePalo Alto, United States
  • Hospital of the University of PennsylvaniaPhiladelphia, United States
  • VCU Health Clinical Research Services UnitRichmond, United States
  • Mayo ClinicRochester, United States
  • UC Davis Medical CenterSacramento, United States
  • University of Utah HospitalSalt Lake City, United States
  • Tampa General Medical GroupTampa, United States
  • Umass Memorial Medical CenterWorcester, United States

About the trial

What the trial wants to find out

The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).

The 2 groups in the trial

  • INT-787Existing treatment, for comparison

    Participants will be randomized to receive INT-787 (in Dose Escalation Cohorts \[Cohorts 1 through 4\] and Extension Phase Cohorts \[Cohorts 5 and 6\])

  • PlaceboPlacebo, for comparison

    Participants will be randomized to receive matching placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis
Record updated
5 May 2026